Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 6.9% – What’s Next?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) was up 6.9% during trading on Tuesday . The stock traded as high as $12.29 and last traded at $12.2170. Approximately 5,496,981 shares changed hands during trading, an increase of 1% from the average daily volume of 5,442,954 shares. The stock had previously closed at $11.43.

Analyst Ratings Changes

A number of research analysts recently weighed in on NTLA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Wednesday, October 8th. William Blair cut Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, October 27th. Tudor Pickering set a $14.50 target price on Intellia Therapeutics in a report on Tuesday, October 28th. Oppenheimer set a $27.00 price target on Intellia Therapeutics in a research report on Friday, November 7th. Finally, Chardan Capital cut their price objective on shares of Intellia Therapeutics from $48.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Nine equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $17.00.

Intellia Therapeutics Stock Performance

The stock has a 50-day moving average price of $9.40 and a 200-day moving average price of $12.73. The stock has a market cap of $1.36 billion, a P/E ratio of -2.75 and a beta of 2.05.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.10. The business had revenue of $13.78 million during the quarter, compared to analyst estimates of $14.12 million. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. Intellia Therapeutics’s revenue for the quarter was up 51.6% on a year-over-year basis. During the same period in the previous year, the business posted ($1.34) earnings per share. Sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In other news, EVP James Basta sold 10,397 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $95,756.37. Following the transaction, the executive vice president directly owned 101,528 shares in the company, valued at approximately $935,072.88. This represents a 9.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John M. Leonard sold 34,146 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $314,484.66. Following the transaction, the chief executive officer directly owned 1,013,339 shares in the company, valued at approximately $9,332,852.19. This represents a 3.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 53,051 shares of company stock worth $488,600 over the last 90 days. Corporate insiders own 3.10% of the company’s stock.

Institutional Trading of Intellia Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Headlands Technologies LLC acquired a new position in Intellia Therapeutics during the second quarter valued at $26,000. Blue Bell Private Wealth Management LLC acquired a new stake in Intellia Therapeutics during the third quarter worth about $30,000. Caitong International Asset Management Co. Ltd purchased a new position in Intellia Therapeutics during the third quarter valued at approximately $30,000. Whipplewood Advisors LLC raised its position in Intellia Therapeutics by 114,900.0% during the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock valued at $32,000 after acquiring an additional 3,447 shares in the last quarter. Finally, Advisory Services Network LLC acquired a new position in Intellia Therapeutics in the third quarter valued at approximately $33,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.